Last, the modification of in vitro–generated polyclonal KIR-only NK cells with chimeric antigen receptors (CARs) could emerge as an interesting previously unknown option for tumor-specific NK cell immunotherapy besides conventional CAR NK cells that are majorly KIR−NKG2A+ (82). This evidence concerns the gene KIR3DL1 and neoplasm.